The U.S. psychedelic mushroom market size is expected to reach USD 4,321.0 million by 2030, grow at a CAGR of 11.3% from 2023 to 2030 according to a new report by Grand View Research, Inc. The use of psychedelic mushrooms and other plant-based entheogens is gaining acceptance in the U.S., with a growing movement to decriminalize their use. Several cities and states have taken steps to legalize or decriminalize these substances, leading to a surge in interest and demand.
These products have shown promising results in treating various mental health conditions such as depression, anxiety, PTSD, and addiction. As further research is conducted on their therapeutic potential, demand for these substances is likely to increase.
The primary application of these products offer treatment of depression and anxiety disorders. Psilocybin, the active ingredient in these mushrooms, has been found to alleviate symptoms of depression and anxiety and even induce long-term positive changes in personality and behavior. This has sparked growing interest in the use of psilocybin as a potential treatment for other mental health conditions such as PTSD, addiction, and end-of-life anxiety in patients with terminal illnesses.
The growing awareness for mental health and well-being in the U.S. is a major factor driving the demand for psychedelic mushrooms. Traditional treatments for depression, anxiety, and other mental health conditions may not work for everyone, prompting many individuals to seek out alternative therapies, such as psychedelic therapy.
Moreover, there is an increasing interest in natural and plant-based remedies, as people become more aware of the potential risks and side effects of synthetic drugs. Psilocybin, the natural psychoactive compound found in psychedelic mushrooms, has been used for centuries by indigenous cultures for spiritual and therapeutic purposes. As the interest in natural and alternative therapies grows, the demand for psychedelic mushrooms is expected to continue increasing.
Psychedelic mushrooms also offer a potential treatment for cluster headaches, which are severe and often resistant to traditional treatments. Psilocybin has demonstrated effectiveness in reducing the frequency and severity of cluster headaches in some patients, offering new hope for individuals who suffer from this debilitating condition.
Request a free sample copy or view report summary: U.S. Psychedelic Mushroom Market Report
The psilocybe type segment led the market in terms of revenue owing to increasing research into their therapeutic potential, and a growing trend towards natural and holistic health practices.
The processed form segment is the fastest growing in the concentration segment owing to easier to consume than dried mushrooms and more consistent dose of psilocybin.
De-addiction is the fastest growing application segment during the projected period of 2022-2030 as psilocybin, found in psychedelic mushrooms, is a potential treatment for substance abuse when paired with therapy.
Grand View Research has segmented the U.S. psychedelic mushroom market based on product, form, application, and country.
U.S. Psychedelic Mushroom Product Outlook (Revenue, USD Million, 2017 - 2030)
Psilocybe
Psilocybe cubensis
Psilocybe semilanceata
Psilocybe azurescens
Psilocybe cyanescens
Psilocybe baeocystis
Gymnopilus
Spectabilis
Others
Panaeolus
U.S. Psychedelic Mushroom Form Outlook (Revenue, USD Million, 2017 - 2030)
Fresh/Whole
Dried
Processed
U.S. Psychedelic Mushroom Application Outlook (Revenue, USD Million, 2017 - 2030)
Depression Relief
Anxiety Relief
De-addiction
Recreational
Others
U.S. Psychedelic Mushroom Country Outlook (Revenue, USD Million, 2017 - 2030)
U.S.
List of Key Players in the U.S. Psychedelic Mushroom Market
Shroomland
Galaxy Treats
Blissmushrooms
oneupmushroomsbar.com
Psychedelic Mushy
Psilocybin Lounge
"The quality of research they have done for us has been excellent..."